Back |
home / stock / hmtxf / hmtxf message board
Subject | By | Source | When |
---|---|---|---|
IR CONSULTING HEAD: The companys lead candidate for phase 2 clinical-stage trial is doing wonders in | IR_CONSULTING_HEAD | investorshangout | 04/13/2022 2:20:21 PM |
IR CONSULTING HEAD: The company's market capitalization is at $10.2M, holding the water from floodin | IR_CONSULTING_HEAD | investorshangout | 04/13/2022 2:18:58 PM |
IR CONSULTING HEAD: Hemostemix has completed a detailed audit of the data received to ensure the aut | IR_CONSULTING_HEAD | investorshangout | 04/13/2022 2:17:38 PM |
IR CONSULTING HEAD: The ongoing dispute between aspiring health science has finally met its end as a | IR_CONSULTING_HEAD | investorshangout | 04/13/2022 2:15:57 PM |
IR CONSULTING HEAD: Hemostemix is a biotechnology-based clinical-stage company listed on the OTC mar | IR_CONSULTING_HEAD | investorshangout | 04/13/2022 2:06:28 PM |
News, Short Squeeze, Breakout and More Instantly...
Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it was notified by the World Intellectual Property Organization that it was granted the trademark Your Fountain of Youth by the Swiss Trademark Office. "In four h...
2024-06-03 13:23:23 ET In a press release this morning, %Hemostemix Inc. (TSXV: $HEM) (OTC: $HMTXF) announced it had signed a Letter of Intent ("LOI") with CytoImmune Therapeutics. The LOI will re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manu...
Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it has signed a Letter of Intent ("LOI") with CytoImmune Therapuetics ("CytoImmune") to re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art c...